Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
17.89
+0.07 (0.39%)
At close: Nov 28, 2025, 1:00 PM EST
17.83
-0.06 (-0.34%)
After-hours: Nov 28, 2025, 4:26 PM EST
Summit Therapeutics Employees
Summit Therapeutics had 159 employees as of December 31, 2024. The number of employees increased by 54 or 51.43% compared to the previous year.
Employees
159
Change (1Y)
54
Growth (1Y)
51.43%
Revenue / Employee
n/a
Profits / Employee
-$5,796,333
Market Cap
13.80B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 159 | 54 | 51.43% |
| Dec 31, 2023 | 105 | 28 | 36.36% |
| Dec 31, 2022 | 77 | -33 | -30.00% |
| Dec 31, 2021 | 110 | 29 | 35.80% |
| Dec 31, 2020 | 81 | 11 | 15.71% |
| Dec 31, 2019 | 70 | 9 | 14.75% |
| Dec 31, 2018 | 61 | -15 | -19.74% |
| Dec 31, 2017 | 76 | 36 | 90.00% |
| Dec 31, 2016 | 40 | 3 | 8.11% |
| Dec 31, 2015 | 37 | 14 | 60.87% |
| Dec 31, 2014 | 23 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SMMT News
- 10 days ago - Summit: A Cautious Bet Backed By Anti-VEGF & Insider Buying - Seeking Alpha
- 10 days ago - Summit Therapeutics Inc. (SMMT) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 18 days ago - Summit Therapeutics Inc. (SMMT) Presents at UBS Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 22 days ago - Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China - Business Wire
- 25 days ago - Summit Therapeutics to Present at Upcoming Investor Conferences - Business Wire
- 4 weeks ago - Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025 - Business Wire
- 4 weeks ago - 1 Monster Stock in the Making to Buy and Hold - The Motley Fool
- 5 weeks ago - Summit Therapeutics: A Risky Bet in the Biotech Arena? - The Motley Fool